A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Erlotinib

Erlotinib 150 mg/day q 4 weeks

DIETARY_SUPPLEMENT

Silybin-phytosome

Silybin-phytosome 1g bid/day q 4 weeks

Trial Locations (1)

RECRUITING

Gosin University Gospel Hospital, Busan